country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-172091

Copy Link Print Information

CZY43

CZY43 is a HER3 degrader with a DC₅₀ of 559 nM. CZY43 induces HER3 degradation via autophagy, inhibits HER3-dependent signaling pathways, suppresses downstream PI3K/Akt signaling, and thereby inhibits tumor cell proliferation and cell adhesion. CZY43 can be used in studies of breast cancer and non-small cell lung cancer.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

화학식: C₄₂H₅₃Cl₂N₅O₃
분자량:746.81

보관:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (281 KB)

CZY43 Chemical Structure

Amount: USD 0.00

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

Use of MCE Products

One-stop solution for XDC (ADC/PDC/RDC/ApDC/FDC/ISAC/VDC/SMDC)

Biological Activity
- 제품 설명
- IC₅₀ & Target
- Cellular Effect
- In Vitro
Chemical Information
순도&문서
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

제품 설명

IC₅₀ & Target

^[1]

HER3

559 nM (DC₅₀)

Akt

All EGFR Isoforms :

All Akt Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
SK-BR-3	IC50	0.53 μM	Antiproliferative activity against breast cancer SKBR3 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay. Antiproliferative activity against breast cancer SKBR3 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay.	39818014

In Vitro

Anti-cancerAutophagy

Anti-cancer

CZY43 (compound 6d) (1-3 μM; 8 h) potently degrades HER3 in breast cancer SKBR3 cells. After 8 h of treatment, the degradation rate reaches 67% at 1 μM and 96% at 3 μM^[1].
CZY43 (0-2000 nM; 0-24 h) induces dose- and time-dependent degradation of HER3 in breast cancer SKBR3 cells, and effectively reduces HER3 protein levels in breast cancer MDA-MB-453 cells and non-small cell lung cancer A549 cells^[1].
CZY43 (125 nM-2000 nM; 8 h) potently inhibits the HER3-dependent signaling pathway in breast cancer SKBR3 cells by reducing the protein levels of HER3 and phosphorylated AKT in a dose-dependent manner^[1].
CZY43 potently inhibits the proliferation of breast cancer SKBR3 cells with an IC₅₀ of 0.53 μM, and reduces the adhesion capacity of SKBR3 cells in a dose-dependent manner^[1].

Anti-cancer

Autophagy

CZY43 (1 μM; 8 h) induces HER3 degradation in breast cancer SKBR3 cells via autophagy, as evidenced by enhanced Hsp90-HER3 binding, increased HER3 ubiquitination, reversal of this degradation process by Chloroquine (HY-17589A), and dose-dependent activation of LC3B^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:

breast cancer SKBR3 cells
Concentration:

1 μM; 3 μM
Incubation Time:

8 h
Result:

Degraded HER3 by 67 % at 1 μM after 8 h.
Degraded HER3 by 96 % at 3 μM after 8 h.

Western Blot Analysis^[1]

Cell Line:

breast cancer SKBR3 cells, breast cancer MDA-MB-453 cells, non-small cell lung cancer A549 cells
Concentration:

0, 125, 250, 500, 1000, 2000 nM (dose-dependent)
1000 nM (time-dependent)
Incubation Time:

8 h (dose-dependent)
0, 2, 4, 8, 12, 24 h (time-dependent)
Result:

Induced dose-dependent HER3 degradation in SKBR3 cells over 8 h.
Induced time-dependent HER3 degradation in SKBR3 cells across multiple timepoints.
Effectively reduced HER3 protein levels in MDA-MB-453 and A549 cells.

Western Blot Analysis^[1]

Cell Line:

breast cancer SKBR3 cells
Concentration:

125 nM, 250 nM, 500 nM, 1000 nM, 2000 nM
Incubation Time:

8 h
Result:

Dose-dependently reduced HER3 and p-AKT protein levels in SKBR3 cells, with more potent inhibition than bosutinib.

Related Protocols :

Chemical Information

분자량 746.81
화학식 C₄₂H₅₃Cl₂N₅O₃
SMILES

COC1=CC(NC2=C(C=NC3=C2C=C(C(OCCCN4CCC5(CCN(CC5)CCC6(C7)C[C@@H]8C[C@@H](C[C@H]7C8)C6)CC4)=C3)OC)C#N)=C(C=C1Cl)Cl
선적

Room temperature in continental US; may vary elsewhere.
보관

Please store the product under the recommended conditions in the Certificate of Analysis.

순도&문서

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (281 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Chen Z, et al. Discovery of CZY43 as a new small-molecule degrader of pseudokinase HER3. European journal of medicinal chemistry. 2025 Mar 05;285:117258. [Content Brief]

Calculators

몰농도 계산기

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

농도 희석 계산기

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

견적 받기 해외재고보유

Other size

견적 받기

Amount: USD 0.00

Biological Activity
- 제품 설명
- IC₅₀ & Target
- In Vitro
Chemical Information
순도&문서
References

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent:

상품명:
CAS No.:
Species:
Purity:
수량:

CZY43

All EGFR Isoforms

All Akt Isoforms

Biological Activity

제품 설명

IC50 & Target

Cellular Effect

In Vitro

Chemical Information

순도&문서

References

Calculators

Help & FAQs

CZY43 Related Classifications

HY-172091 Related Classifications

Bioz

Keywords

Your Recently Viewed Products

IC₅₀ & Target